In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Eric Van Cutsem argues that the preferred salvage therapy for metastatic colorectal cancer (mCRC) is regorafenib followed by TAS-102.
A continuing education program is offered as a supplement to this webcast at the following location:
http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205
© 2016 Imedex, LLC.